An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study

An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study - An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038559

Enrollment

200

Registered

2019-11-13

Start date

2017-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary bladder cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with muscle invasive bladder cancer Patients with frailty evaluation before surgery or trimodal therapy for bladder preservation

Exclusion criteria

Exclusion criteria: Patients with bladder cancer who were not eligible for radical therapy such as radical cystectomy or trimodal therapy for bladder preservation

Design outcomes

Primary

Measure	Time frame
Primary purpose was the comparison of frailty between the patients who underwent radical cystectomy (RC group) and trimodal therapy for bladder preservation (TMT group).	—

Secondary

Measure	Time frame
Secondary purposes included the prevalence of frailty and the effect of frailty on treatment selection between the RC and TMT groups. This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.	—

Measure

Time frame

Secondary purposes included the prevalence of frailty and the effect of frailty on treatment selection between the RC and TMT groups. This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.

—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Hirosaki University School of Medicine Urology

shingoh@hirosaki-u.ac.jp+81172395091

Outcome results